CT and MRI in monitoring response: State-of-the-art and future developments

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 6, 2011, Pages 603-619

  D'Ippolito, G ^a   Torres, L R ^a   Saito Filho, C F ^a   Ferreira, R M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Magnetic resonance imaging; Medical oncology; Tomography, X ray computed

Indexed keywords

CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE QUALITY; IONIZING RADIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PERFUSION WEIGHTED IMAGING; RADIOLOGICAL PARAMETERS; REPRODUCIBILITY; REVIEW; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR IMAGING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84857616389     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Gwyther SJ. Current standards for response evaluation by imaging techniques. Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:11-5.
2. Provenzale JM. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 2007;188:11-23. (Pubitemid 46012485)
3. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010;20:1456-67.
4. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010;195:281-9.
5. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST). Invest Radiol 2011 [Epub ahead of print].
6. Gwyther SJ, Schwartz LH. How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 2008;44:39-45. (Pubitemid 350256945)
7. Biederer J, Dinkel J, Remmert G, Jetter S, NiIl S, Moser T et al. 4D-Imaging of the lung: reproducibility of lesion size and displacement on helical CT, MRI, and cone beam CT in a ventilated ex vivo system. Int J Radiat Oncol Biol Phys 2009;73:919-26.
8. Pauls S, Kurschner C, Dharaiya E, Muche R, Schmidt SA, Krüger S et al. Comparison of manual and automated size measurements of lung metastases on MDCT images: potential influence on therapeutic decisions. Eur J Radiol 2008;66:19-26. (Pubitemid 351434531)
9. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006;6:S126-30.
10. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009;72:217-38.
11. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010;5:95-112.
12. Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 2011;259:574-82.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
14. Serkova NJ. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat 2011;14:224-35.
15. Jaffe TA, Wickersham NW, Sullivan DC. Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. AJR Am J Roentgenol 2010;195:101-6.
16. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
18. Suzuki, Torkzad MR, Jacobsson H, Aström G, Sundin A, Hatschek T et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010;49:509-14.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92-205-16.
20. Chojniak R, Yu LS, Younes RN. Response to chemotherapy in patients with lung metastases: how many nodules should be measured? Cancer Imaging 2006,6:107-12.
21. Prasad SR, Saini S, Sumner JE, Hahn PF, Sahani D, Boland GW. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr 2003;27:380-4. (Pubitemid 36793188)
22. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011;52:48-55.
23. Vilgrain V. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 2010;17:374-9.
24. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803-9.
25. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-56.
26. Mabille M, Vanel D, Albiter M, Le Cesne A, Bonvalot S, Le Pechoux C et al. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). Eur J Radiol 2009;69:204-8.
27. Zander T, Scheffler M, Nogova L, Kobe, Engel-Riedel W, Hellmich M et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011;29:1701-8.
28. Pope WB, Young JR, Ellingson BM. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011;11:336-44.
29. Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 2010;85:1-10.
30. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
31. Van Beers BE, Vilgrain V. Biomarkers in abdominal imaging. Abdom Imaging 2009;34:663-7.
32. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4. (Pubitemid 46797958)
33. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194:1470-8.
34. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13 Suppl 2:4-7.
35. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9. (Pubitemid 46797957)
36. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194:157-65.
37. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
38. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009;19:2728-38.
39. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13:770s-6s.
40. Kim SH, Lee JM, Hong SH, Kim GH, Lee JY, Han JK, Choi BI. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009;253:116-25.
41. Birchard KR, Hoang JK, Herndon JE, Jr., Patz EF, Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009;115:581-6.
42. Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T. Post-treatment imaging of liver tumours. Cancer Imaging 2007;7 Spec No A:S28-36.
43. Bevelacqua JJ. Practical and effective ALARA. Health Phys 2010;98:S39-47.
44. Marin D, Nelson RC, Rubin GD, Schindera ST. Body CT: Technical Advances for Improving Safety. AJR Am J Roentgenol 2011;197:33-41.
45. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
46. Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D et at. The optimal contrast media policy in CT of the liver. Part II: Clinical protocols. Acta Radiol 2011;52:473-80.
47. Silverman PM. Liver metastases: imaging considerations for protocol development with multislice CT (MSCT). Cancer Imaging 2006;6:175-81.
48. Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 2010;256:32-61.
49. Soyer P, Bluemke DA, Rymer R. MR imaging of the liver. Technique. Magn Reson Imaging Clin N Am 1997;5:205-21.
50. Scott DJ, Guthrie JA, Arnold P, Ward J, Atchley J, Wilson D et al. Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intraoperative sonography, surgical and pathological findings. Clin Radiol 2001;56:235-42.
51. Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y et al. Imaging liver metastases: review and update. Eur J Radiol 2006;58:217-28.
52. Haider MA, Amitai MM, Rappaport DC, O'Malley ME, Hanbidge AE, Redston M et al. Multi-detector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better? Radiology 2002;225:137-42.
53. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transi Sci 2009;2:15-25.
54. Bhure UN, Lardinois D, Kalff V, Hany TF, Soltermann A, Seifert B et al. Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements. Br J Radiol 2010;83:841-9.
55. Lavini C, Verhoeff JJ. Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging 2010;28:1420-30.
56. Vlieger EJ, Lavini C, Majoie CB, den Heeten GJ. Reproducibility of functional MR imaging results using two different MR systems. AJNR Am J Neuroradiol 2003;24:652-7. (Pubitemid 36460735)
57. Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 2009;50:239-49.
58. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 2003;227:633-8. (Pubitemid 36583016)
59. Bellomi M, Viotti S, Preda L, D'Andrea G, Bonello L, Petralia G. Perfusion CT in solid body-tumours. Part II: Clinical applications and future development. Radiol Med 2010;115:858-74.
60. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003;76 Spec No 1:S36-42. (Pubitemid 39530314)
61. Schramm P, Huang Y, Erb G, Klotz E, Heiland S. How does the injection protocol influence the attenuation-time curve in CT perfusion measurements: comparison of measured and simulated data. Med Phys 2009:36:3487-94.
62. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007;244:486-93. (Pubitemid 47080881)
63. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999:30:198-205. (Pubitemid 29343737)
64. Meijerink MR, van Cruijsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe JH et al. The use of perfusion CT for the evaluation of therapy combining AZD217, with gefitinib in cancer patients. Eur Radiol 2007;17:1700-13. (Pubitemid 46909659)
65. Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R et al. Reproducibility of CT Perfusion Parameters in Liver Tumors and Normal Liver. Radiology 2011;260:762-70.
66. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011;55:858-65.
67. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol 2003;76:220-31. (Pubitemid 36582066)
68. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008;13(Suppl 2):32-40.
69. Marten K, Auer F, Schmidt S, Kohl G, Rummeny EJ, Engelke C. Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol 2006;16:781-90. (Pubitemid 43380236)
70. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd L et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009;45:290-9.
71. Yoshimura K, Kato H, Kuroda M, Yoshida A, Hanamoto K, Tanaka A et al. Development of a tissue-equivalent MRI phantom using carrageenan gel. Magn Reson Med 2003;50:1011-7. (Pubitemid 37356581)
72. Wormanns D, Kohl G, Klotz E, Marheine A, Beyer F, Heindel W et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol 2004;14:86-92. (Pubitemid 38181058)
73. Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth: assessment with CT - comparison of diameter and cross-sectional area with volume measurements. Radiology 2004;231:866-71. (Pubitemid 38668110)
74. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010;11:92-102.
75. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007;9:1003-11. (Pubitemid 350255347)
76. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:708-10. (Pubitemid 37021839)
77. Dale BM, Braithwaite AC, Boll DT, Merkle EM. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol 2010;45:104-8.
78. Ogura A, Hayakawa K, Miyati T, Maeda F. Imaging parameter effects in apparent diffusion coefficient determination of magnetic resonance imaging. Eur J Radiol 2011;77:185-8.
79. Arlinghaus LR, Li X, Levy M, Smith D, Welch EB, Gore JC et al. Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010; 2010. pii: 919620. Epub 2010 Sep 29.
80. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-25.
81. Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008;190:67-73.
82. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35:309-21.
83. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42. (Pubitemid 46621830)
84. O'Connor JP, Carano RA, Clamp AR, Tozer GM, Wilson J, Taylor NJ et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82.
85. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-59. (Pubitemid 46955104)
86. Goh V, Padhani AR. Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging 2006;31:194-9.
87. Seierstad T, Roe K, Olsen DR. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol 2007;85:187-94. (Pubitemid 350161006)
88. Assumpcao L, Choti M, Pawlik TM, Gecshwind JF, Kamel IR. Functional MR imaging as a new paradigm for image guidance. Abdom Imaging 2009;34:675-85.
89. Kwock L, Smith JK, Castillo M, Ewend MG, Collichio F, Morris DE et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006;7:859-68. (Pubitemid 44464079)
90. Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. J Comput Assist Tomogr 2008;32:987-94.
91. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S et al. Monitoring of neoadjuvant chemotherapy using multiparametric, (2)(3)Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat 2011;128:119-26.
92. Dyke JP, Sanelli PC, Voss HU, Serventi JV, Stieg PE, Schwartz TH et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J Neurooncol 2007;82:103-10.
93. Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G et al. Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:262-8.
94. Lin YC, Wang CC, Wai YY, Wan YL, Ng SH, Chen YL et al. Significant temporal evolution of diffusion anisotropy for evaluating early response to radiosurgery in patients with vestibular schwannoma: findings from functional diffusion maps. AJNR Am J Neuroradiol 2010;31:269-74.
95. Hsu YY, Kuan WC, Lim KE, Liu HL. Breathhold-regulated blood oxygenation level-dependent (BOLD) MRI of human brain at 3 tesla. J Magn Reson Imaging 2010;31:78-84.
96. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med 2008;38:199-208. (Pubitemid 351466918)
97. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol 2008;18:1077-86.
98. Somer EJ, Marsden PK, Benatar NA, Goodey J, O'Doherty MJ, Smith MA. PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques. Eur J Nucl Med Mol Imaging 2003;30:54-62. (Pubitemid 36692893)
99. Borgwardt L, Højgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005;23:3030-7. (Pubitemid 46224124)